Related references
Note: Only part of the references are listed.Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?
Elizabeth R. Rayburn et al.
DRUG DISCOVERY TODAY (2008)
Clusterin antisense complexed with chitosan for controlled intratumoral delivery
Christopher M. Springate et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly L-lysine dendrimers
Lisa M. Kaminskas et al.
MOLECULAR PHARMACEUTICS (2008)
Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice
Haifang Yin et al.
MOLECULAR THERAPY (2008)
Breaking the bonds: Non-viral vectors become chemically dynamic
Jon A. Wolff et al.
MOLECULAR THERAPY (2008)
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo
Erik Henke et al.
NATURE BIOTECHNOLOGY (2008)
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Rudy Juliano et al.
NUCLEIC ACIDS RESEARCH (2008)
Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat Chromogranin-A
Gabor Lendvai et al.
OLIGONUCLEOTIDES (2008)
Molecular biology - The art of assembly
Francis Szoka
SCIENCE (2008)
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target
Dan Peer et al.
SCIENCE (2008)
Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA)
Harleen Kaur et al.
CHEMICAL REVIEWS (2007)
Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes
Mausumee Guha et al.
FASEB JOURNAL (2007)
Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate
Adams Amantana et al.
BIOCONJUGATE CHEMISTRY (2007)
ISIS 301012, an antisense inhibitor of APOB, produces significant additional reduction of LDL-C & APOB in hypercholesterolemic subjects on statins not meeting target
J. P. Kastelein et al.
ATHEROSCLEROSIS SUPPLEMENTS (2007)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
2 '-modified oligonucleotides for antisense therapeutics
Thazha P. Prakash et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Lipid-based nanoparticles for nucleic acid delivery
Weijun Li et al.
PHARMACEUTICAL RESEARCH (2007)
Characterization of the acute cardiovascular effects of intravenously administered insulin-like growth factor-I in conscious Sprague-Dawley rats
Nga Cao et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice
Jennifer Roberts et al.
MOLECULAR THERAPY (2006)
A phase I/II clinical trial in Duchenne muscular dystrophy using IM and IV delivered antisense oligonucleotides: The MDEX consortium
V. Arechavala et al.
NEUROMUSCULAR DISORDERS (2006)
Cationic poly-L-lysine dendrimers: Pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats
Ben J. Boyd et al.
MOLECULAR PHARMACEUTICS (2006)
Intravenous insulin-like growth factor-I receptor antisense treatment reduces angiotensin receptor expression and function in spontaneously hypertensive rats
Tien Thuy Nguyen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Polyethylenimine-based antisense oligodeoxynucteotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation
Ji-Hye Seong et al.
JOURNAL OF GENE MEDICINE (2006)
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
J Alter et al.
NATURE MEDICINE (2006)
A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients
JG McHutchison et al.
JOURNAL OF HEPATOLOGY (2006)
Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice
Yuning Sun et al.
OLIGONUCLEOTIDES (2006)
Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain
AC Kilic et al.
JOURNAL OF MICROENCAPSULATION (2005)
Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats
TT Nguyen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides
CM Roth
BIOPHYSICAL JOURNAL (2005)
Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats
G Lendvai et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in vivo conditions in a dose-dependent manner after intravenous injection into mice
T Merdan et al.
BIOCONJUGATE CHEMISTRY (2005)
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide
K Fluiter et al.
CHEMBIOCHEM (2005)
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
GR Devi et al.
CLINICAL CANCER RESEARCH (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis
KJ Myers et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Inhibition of tumor necrosis factor alpha secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides
BC Ponnappa et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells
A Aartsma-Rus et al.
GENE THERAPY (2004)
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
J Marshall et al.
ANNALS OF ONCOLOGY (2004)
Tissue disposition of 2 '-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys
RZ Yu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate
AA Raoof et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury
L Masarjian et al.
OLIGONUCLEOTIDES (2004)
Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology
JS Jepsen et al.
OLIGONUCLEOTIDES (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer
HR Xing et al.
NATURE MEDICINE (2003)
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
QL Lu et al.
NATURE MEDICINE (2003)
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA
A Grünweller et al.
NUCLEIC ACIDS RESEARCH (2003)
Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy
S Kagiyama et al.
HYPERTENSION (2003)
In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides
K Fluiter et al.
NUCLEIC ACIDS RESEARCH (2003)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2 '-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species
RS Geary et al.
DRUG METABOLISM AND DISPOSITION (2003)
Macromolecular therapeutics - Advantages and prospects with special emphasis on solid tumour targeting
K Greish et al.
CLINICAL PHARMACOKINETICS (2003)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues
P Sazani et al.
NATURE BIOTECHNOLOGY (2002)
bis-cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver
MK Bijsterbosch et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions
A Astriab-Fisher et al.
PHARMACEUTICAL RESEARCH (2002)
Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration
BM McMahon et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
In vivo pro-apoptotic and antitumor efficacy of a c-raf antisense phosphorothioate oligonucleotide:: Relationship to tumor size
QC Lau et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Antisense knockdown of inducible nitric oxide synthase inhibits the relaxant effect of VIP in isolated smooth muscle cells of the mouse gastric fundus
JMC Dick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy
CM Ward et al.
BLOOD (2001)
Cationic lipid-based delivery system for systemic cancer gene therapy
K Anwer et al.
CANCER GENE THERAPY (2000)
Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates
A Astriab-Fisher et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Antisense inhibition of β1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats
YC Zhang et al.
CIRCULATION (2000)
General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies
B Kuhnast et al.
BIOCONJUGATE CHEMISTRY (2000)
Share Paper
